Log in

NASDAQ:STML - Stemline Therapeutics Stock Price, Forecast & News

$6.65
-0.18 (-2.64 %)
(As of 02/25/2020 06:54 AM ET)
Today's Range
$6.48
Now: $6.65
$6.81
50-Day Range
$6.38
MA: $7.35
$10.74
52-Week Range
$6.01
Now: $6.65
$18.22
Volume596,057 shs
Average Volume980,374 shs
Market Capitalization$333.36 million
P/E RatioN/A
Dividend YieldN/A
Beta1.44
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STML
CUSIPN/A
Phone646-502-2311

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$1.32 per share

Profitability

Net Income$-85,020,000.00

Miscellaneous

Employees92
Market Cap$333.36 million
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable

Receive STML News and Ratings via Email

Sign-up to receive the latest news and ratings for STML and its competitors with MarketBeat's FREE daily newsletter.


Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics Inc (NASDAQ:STML) posted its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.42) by $0.08. The biopharmaceutical company had revenue of $13.33 million for the quarter, compared to analysts' expectations of $13.40 million. View Stemline Therapeutics' Earnings History.

When is Stemline Therapeutics' next earnings date?

Stemline Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Stemline Therapeutics.

What guidance has Stemline Therapeutics issued on next quarter's earnings?

Stemline Therapeutics issued an update on its FY 2019 After-Hours earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $43.2-43.2 million, compared to the consensus revenue estimate of $46.44 million.

What price target have analysts set for STML?

7 equities research analysts have issued 1 year price objectives for Stemline Therapeutics' stock. Their forecasts range from $14.00 to $33.00. On average, they anticipate Stemline Therapeutics' stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 223.3% from the stock's current price. View Analyst Price Targets for Stemline Therapeutics.

What is the consensus analysts' recommendation for Stemline Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stemline Therapeutics.

Has Stemline Therapeutics been receiving favorable news coverage?

Press coverage about STML stock has trended neutral recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stemline Therapeutics earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Stemline Therapeutics.

Who are some of Stemline Therapeutics' key competitors?

What other stocks do shareholders of Stemline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stemline Therapeutics investors own include TG Therapeutics (TGTX), Exelixis (EXEL), Viking Therapeutics (VKTX), ZIOPHARM Oncology (ZIOP), Gilead Sciences (GILD), Fate Therapeutics (FATE), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Karyopharm Therapeutics (KPTI) and Opko Health (OPK).

Who are Stemline Therapeutics' key executives?

Stemline Therapeutics' management team includes the folowing people:
  • Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 53)
  • Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 59)
  • Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 54)
  • Mr. Robert Francomano, Sr. VP & Global Head of Commercial
  • Mr. John A. Salvagno, Sr. VP of Quality & Operations

Who are Stemline Therapeutics' major shareholders?

Stemline Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Farallon Capital Management LLC (4.69%), State Street Corp (4.31%), Alliancebernstein L.P. (3.76%), Goldman Sachs Group Inc. (2.70%), Sectoral Asset Management Inc (2.04%) and FMR LLC (1.76%). Company insiders that own Stemline Therapeutics stock include Alan S Forman, David Gionco, Ivan Bergstein, Kenneth Hoberman and Robert Francomano. View Institutional Ownership Trends for Stemline Therapeutics.

Which institutional investors are selling Stemline Therapeutics stock?

STML stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, UBS Group AG, Citigroup Inc., Rafferty Asset Management LLC, Schonfeld Strategic Advisors LLC, Goldman Sachs Group Inc., New York State Common Retirement Fund and Cubist Systematic Strategies LLC. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein, Kenneth Hoberman and Robert Francomano. View Insider Buying and Selling for Stemline Therapeutics.

Which institutional investors are buying Stemline Therapeutics stock?

STML stock was acquired by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Alliancebernstein L.P., Rhenman & Partners Asset Management AB, FMR LLC, State Street Corp, Bullseye Asset Management LLC, Empire Life Investments Inc. and Farallon Capital Management LLC. View Insider Buying and Selling for Stemline Therapeutics.

How do I buy shares of Stemline Therapeutics?

Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Stemline Therapeutics' stock price today?

One share of STML stock can currently be purchased for approximately $6.65.

How big of a company is Stemline Therapeutics?

Stemline Therapeutics has a market capitalization of $333.36 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-85,020,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe.View Additional Information About Stemline Therapeutics.

What is Stemline Therapeutics' official website?

The official website for Stemline Therapeutics is http://www.stemline.com/.

How can I contact Stemline Therapeutics?

Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]


MarketBeat Community Rating for Stemline Therapeutics (NASDAQ STML)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  431 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  667
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel